Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr 15;5(6):623-7.
doi: 10.1021/ml500113s. eCollection 2014 Jun 12.

Hybrid dopamine uptake blocker-serotonin releaser ligands: a new twist on transporter-focused therapeutics

Bruce E Blough  1 , Antonio Landavazo  1 , John S Partilla  2 , Michael H Baumann  2 , Ann M Decker  1 , Kevin M Page  1 , Richard B Rothman  2
Affiliations

Hybrid dopamine uptake blocker-serotonin releaser ligands: a new twist on transporter-focused therapeutics

Bruce E Blough et al. ACS Med Chem Lett. .

Abstract

As part of our program to study neurotransmitter releasers, we report herein a class of hybrid dopamine reuptake inhibitors that display serotonin releasing activity. Hybrid compounds are interesting since they increase the design potential of transporter related compounds and hence represent a novel and unexplored strategy for therapeutic drug discovery. A series of N-alkylpropiophenones was synthesized and assessed for uptake inhibition and release activity using rat brain synaptosomes. Substitution on the aromatic ring yielded compounds that maintained hybrid activity, with the two disubstituted analogues (PAL-787 and PAL-820) having the most potent hybrid activity.

Keywords: Dopamine uptake inhibitors; cocaine; methamphetamine; serotonin receptor; serotonin releasers.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Propiophenone compounds.
Scheme 1
Scheme 1. Synthesis of Hybrid Analogues
(a) Br2, MeOH; (b) cyclopropylamine.
See this image and copyright information in PMC

References

    1. Carroll F. I.; Blough B. E.; Abraham P.; Mills A. C.; Holleman J. A.; Wolckenhauer S. A.; Decker A. M.; Landavazo A.; McElroy K. T.; Navarro H. A.; Gatch M. B.; Forster M. J. Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J. Med. Chem. 2009, 52, 6768–81. - PubMed
    1. Glennon R. A.; Yousif M.; Naiman N.; Kalix P. Methcathinone: A new and potent amphetamine-like agent. Pharmacol., Biochem. Behav. 1987, 26, 547–551. - PubMed
    1. Nielsen J. A.; Shannon N. J.; Bero L.; Moore K. E. Effects of acute and chronic bupropion on locomotor activity and dopaminergic neurons. Pharmacol., Biochem. Behav. 1986, 24, 795–9. - PubMed
    1. Sparago M.; Wlos J.; Yuan J.; Hatzidimitriou G.; Tolliver J.; Dal Cason T. A.; Katz J.; Ricaurte G. Neurotoxic and pharmacologic studies on enantiomers of the N-methylated analog of cathinone (methcathinone): a new drug of abuse. J. Pharmacol. Exp. Ther. 1996, 279, 1043–52. - PubMed
    1. Gowrishankar R.; Hahn M. K.; Blakely R. D. Neurochem. Int. 2013, 10.1016/j.neuint.2013.10.016. - DOI - PubMed